尼莫地平片治疗急性脑出血患者的临床研究分析  

Clinical trial analysis of nimodipine tablets in the treatment of patients with acute cerebral hemorrhage

作　　者：刘显国 李胜利[3] 黄国祥[3] 马松华[2] LIU Xian-guo;LI Sheng-li;HUANG Guo-xiang;MA Song-hua(Department of Pharmacy,The Second PeopleJ s Hospital of Nantong,Nantong 226001,Jiangsu Province,China;Department of Neurology,The Second PeopleJ s Hospital of Nantong,Nantong 226001,Jiangsu Province,China;Department of Neurology,The First People5 s Hospital of Nantong,Nantong 226001,Jiangsu Province,China)

机构地区：[1]南通市第二人民医院药剂科,江苏南通226001 [2]南通市第二人民医院神经内科,江苏南通226001 [3]南通市第一人民医院神经内科,江苏南通226001

出　　处：《中国临床药理学杂志》2022年第4期296-299,共4页The Chinese Journal of Clinical Pharmacology

基　　金：江苏省自然科学基金资助项目(BK20150998)。

摘　　要：目的观察尼莫地平片治疗急性脑出血患者的临床疗效及安全性。方法将126例患者根据治疗方法分为对照组和试验组,每组63例。所有患者均给予脑出血常规治疗,在此基础上,对照组在发病后12 h内给予尼莫地平每次30mg,tid,口服;试验组在发病后> 12 h给予尼莫地平每次30 mg,tid,口服。2组患者均持续治疗2周。比较2组患者的临床疗效,中性粒细胞明胶酶相关载脂蛋白(NGAL)、降钙素基因相关肽(CGRP)、脑源性神经营养因子(BDNF),以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为80.95%(51例/63例)和93.65%(59例/63例),差异无统计学意义(P> 0.05)。治疗后,试验组和对照组的NGAL分别为(44.31±10.15)和(32.03±9.77)ng·mL^(-1),CGRP分别为(50.11±9.21)和(61.03±10.56) pg·mL^(-1),BDNF分别为(2.21±0.87)和(2.98±0.94) ng·mL^(-1),差异均有统计学意义(均P <0.05)。对照组的药物不良反应主要有急性肾损伤和消化道反应,试验组的药物不良反应主要有急性肾损伤、皮疹和消化道反应。试验组和对照组的总药物不良反应发生率分别为14.29%和9.52%,差异无统计学意义(P>0.05)。结论尼莫地平片治疗急性脑出血具有较好的临床疗效和安全性,其能降低NGAL水平,提高CGRP和BCNF水平,且在发病后12 h内给予效果更好。Objective To observe the clinical efficacy and safety of nimodipine tablets in the treatment of patients with acute cerebral hemorrhage. Methods According to the method of treatment,126 patients were divided into control and treatment groups with 63 cases per group. All patients were given routine treatment of cerebral hemorrhage.On this basis,the control group was given nimodipine 30 mg per time,tid,orally within 12 h after onset. The treatment group was given nimodipine 30 mg per time,tid,orally more than 12 h after onset. Two groups were treated for 2 weeks. The clinical efficacy, neutrophil gelatinase-associated lipocalin( NGAL), calcitonin gene-related peptide( CGRP),brain-derived neurotrophic factor( BDNF) and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups were 80. 95%( 51 cases/63 cases) and 93. 65%( 59 cases/63 cases) without significant difference( P > 0. 05). After treatment,the NGAL of treatment and control groups were( 44. 31 ± 10. 15) and( 32. 03 ± 9. 77) ng·mL^(-1),CGRP were( 50. 11 ± 9. 21) and( 61. 03 ± 10. 56) pg·mL^(-1),BDNF were( 2. 21 ± 0. 87) and( 2. 98 ± 0. 94) ng·mL^(-1),the differences were statistically significant( all P <0. 05).The adverse drug reactions of control group were acute kidney injury and digestive tract reaction,which in treatment group were acute kidney injury,rash and digestive tract reaction. The total incidences of adverse drug reactions in the treatment and control groups were 14. 29% and 9. 52% without significant difference( P > 0. 05). Conclusion Nimodipine tablets have a definitive clinical efficacy and safety in the treatment of patients with acute cerebral hemorrhage,which can reduce the level of NGAL and improve the levels of CGRP and BCNF,and the effect was better within 12 h.

关 键 词：尼莫地平片 急性脑出血 中性粒细胞明胶酶相关载脂蛋白 降钙素基因相关肽 脑源性神经营养因子 安全性评价 

分 类 号：R972[医药卫生—药品]